Group 1 - The company expects to achieve a net profit of RMB 660 million to RMB 680 million for the six months ending June 30, 2025, compared to a net loss of RMB 735 million to RMB 755 million for the same period in 2024 [1] - The primary reason for the expected change in net profit is the increase in gains from the change in the fair value of financial instruments issued to investors, which is expected to increase by RMB 795 million to RMB 815 million compared to the loss in the same period last year [1] Group 2 - The adjusted net profit attributable to shareholders (non-HKFRS measure) is expected to be between RMB 56 million and RMB 76 million for the six months ending June 30, 2025, a decrease of RMB 50 million to RMB 70 million compared to the same period in 2024 [2] - The expected decline in adjusted net profit is primarily due to increased uncertainty in the macroeconomic environment, a slowdown in financial consumer demand, and the implementation of a unified reporting policy in the insurance industry that has reduced insurance brokerage fees [2] - The company's revenue for the six months ending June 30, 2025, is projected to be approximately RMB 545 million to RMB 565 million, a decrease of about RMB 140 million to RMB 160 million compared to the same period in 2024 [2] - Costs and expenses are expected to decrease by approximately RMB 75 million to RMB 95 million, which is lower than the decline in revenue [2]

Group 1 - The company expects to achieve a net profit of RMB 660 million to RMB 680 million for the six months ending June 30, 2025, compared to a net loss of RMB 735 million to RMB 755 million for the same period in 2024 [1] - The primary reason for the change in net profit expectation is the increase in gains from the change in the fair value of financial instruments issued to investors, which is expected to increase by RMB 795 million to RMB 815 million compared to the loss in the same period last year [1] Group 2 - The adjusted net profit attributable to shareholders (non-HKFRS measure) is expected to be between RMB 56 million and RMB 76 million for the six months ending June 30, 2025, a decrease of RMB 50 million to RMB 70 million compared to the same period in 2024 [2] - The expected decline in adjusted net profit is primarily due to increased uncertainty in the macroeconomic environment, a slowdown in financial consumer demand, and the implementation of a unified reporting policy in the insurance industry that reduces brokerage fees [2] - The company's revenue for the six months ending June 30, 2025, is projected to be approximately RMB 545 million to RMB 565 million, a decrease of about RMB 140 million to RMB 160 million compared to the same period in 2024 [2] - Costs and expenses are expected to decrease by approximately RMB 75 million to RMB 95 million, which is lower than the decline in revenue [2]

Core Viewpoint - The company expects to report a net profit of between RMB 660 million and RMB 680 million for the six months ending June 30, 2025, a significant improvement compared to a net loss of between RMB 735 million and RMB 755 million for the same period in 2024 [1] Group 1 - The primary reason for the expected change in net profit is an increase in the fair value change of financial instruments issued to investors, which is anticipated to contribute a gain of between RMB 795 million and RMB 815 million compared to a loss in the previous year [1] - The adjusted net profit attributable to shareholders (non-HKFRS measure) is expected to be between RMB 56 million and RMB 76 million, a decrease of between RMB 50 million and RMB 70 million compared to the same period in 2024 [2] - The anticipated decline in adjusted net profit is attributed to increased uncertainty in the macroeconomic environment, a slowdown in financial consumer demand, and the implementation of a unified reporting policy in the insurance industry that has reduced brokerage fees [2] Group 2 - The company's revenue for the six months ending June 30, 2025, is projected to be between RMB 545 million and RMB 565 million, representing a decrease of between RMB 140 million and RMB 160 million compared to the same period in 2024 [2] - Costs and expenses are expected to decrease by between RMB 75 million and RMB 95 million, which is lower than the revenue decline [2] - Despite the anticipated challenges, the board believes that the overall operational, financial condition, and cash flow of the company remain robust [2]

手回集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2621） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Shouhui Group Limited 附註1： 經調整的股東應佔淨利潤是扣除以股份為基礎的薪酬開支、上市開支及向投資者發行的 金融工具賬面值變動的利潤╱（損失）。 本公告所載資料基於董事會可獲得的最新財務資料以及本集團截至2025年6月30日 止六個月的未經審核綜合管理賬目，該賬目未經本公司審計師審閱或審核。 盈利警告 本公告乃由手回集團有限公司（「本公司」，連同其附屬公司及通過合約安排控制的 實體，統稱「本集團」）根據《香港聯合交易所有限公司證券上市規則》（「上市規則」） 第13.09(2)條及香港法例第571章證券及期貨條例第XIVA部項下之內幕消息條文 （定義見上市規則）而作出。 本公司董事（「董事」）會（「董事會」）謹此通知本公司股東（「股東」）及潛在投資者，本 集團預計將錄得截至2025年6月30日止六個月的淨利潤 ...

Core Viewpoint - The stock price of Shouhui Group (02621.HK) has reached a low of 4.65 HKD, reflecting a decline of 0.64% as of the latest trading session, indicating potential concerns regarding its market performance [1] Group 1: Company Performance - Shouhui Group's stock hit a low of 4.65 HKD on July 7, 2023, and has returned to this level again [1] - The closing price today is reported at 4.67 HKD, showing a slight decrease [1] Group 2: Investment Insights - Gao Fei Asset, a subsidiary of Noah Wealth, is the largest external institutional shareholder of Shouhui Group, having invested 150 million RMB in the company's Series C financing in 2020 [1] - Gao Fei Asset's investment decision was based on a deep understanding of the internet personal insurance sector and the company's core capabilities [1] Group 3: IPO Details - Shouhui Group was listed on the Hong Kong Stock Exchange on May 30, 2025, with an initial offering price of 8.08 HKD [1] - The total amount raised from the IPO was 196.82 million HKD, with net proceeds of 134.22 million HKD after deducting estimated listing expenses of 62.59 million HKD [1]

第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年7月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 手回集團有限公司 | | | 呈交日期: | 2025年8月4日 | | | I. 法定/註冊股本變動 | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02621 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | ...

Core Viewpoint - The company, Shouhui Group, has entered into agreements with Pudong Development Bank and Pudong Bank Wealth Management for fixed income investment products, indicating a strategic move to enhance its investment portfolio [1] Group 1: Investment Agreements - On June 5, 2025, Shouhui Group, through its controlled entity in Shenzhen, signed an agreement with Pudong Development Bank and Pudong Bank Wealth Management to invest in a fixed income product with a principal amount of RMB 5,000,000 [1] - On July 30, 2025, Shouhui Group further committed to the same fixed income product by entering into a new agreement with a principal amount of RMB 45,000,000 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Shouhui Group Limited 手回集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2621） 須予披露交易 認購理財產品 認購理財產品 | 認購日期 | ： | 2025年7月30日 | | --- | --- | --- | | 訂約方 | : (i) | 深圳手回，作為認購人 | | | (ii) | 浦發銀行，作為產品托管人及銷售機構 | | | (iii) | 浦銀理財，作為發行人及產品管理人 | | 理財產品名稱 | ： | 浦銀理財日添金1號（公司專屬）理財產品 | | 產品類型 | ： | 固定收益、公募開放式淨值型 | | 產品投資範圍 | ： | 本產品主要投資於： | | | (i) | 指定固定收益資產，包括現金、銀行存款、同業存 款、拆借、回購、貨幣基金等貨幣市場工具；國 | | | | 債、地方政府債、央行票據、同業存單等符合監管 | | | | 要求 ...

Core Viewpoint - The article discusses the IPO plans of Shanghai Meixin Health Technology Group Co., Ltd. in Hong Kong, highlighting its position as a leading provider of innovative pharmaceutical and insurance solutions in China [2][6]. Company Overview - Shanghai Meixin Health was established in 2017 and is recognized as a prominent multi-payment platform in the pharmaceutical sector. The company has developed two main industry solutions: Smart Drug Solutions for pharmaceutical companies and Smart Insurance Solutions for insurance firms [2]. - As of December 31, 2024, Meixin Health is projected to have served approximately 393 million insurance policies and collaborated with over 140 pharmaceutical companies and more than 90 insurance companies [2]. Financial Performance - The company's revenue for the years 2022, 2023, and 2024 is reported as 1.069 billion, 1.255 billion, and 2.035 billion yuan respectively, indicating a significant growth trend [3]. - Gross profit figures for the same years are 332 million, 461 million, and 729 million yuan, reflecting a positive growth trajectory [3]. - Despite ongoing losses, the adjusted net loss decreased from 447 million yuan in 2022 to 290 million yuan in 2023, and is expected to further reduce to 80 million yuan in 2024, showing a trend of narrowing losses [4]. Industry Outlook - According to Frost & Sullivan, the market size for innovative pharmaceutical and medical device solutions in China is expected to grow from 162 billion yuan in 2024 to 410.2 billion yuan by 2030, with a compound annual growth rate (CAGR) of 16.7% [4]. - The commercial health insurance market in China is projected to expand from 977.3 billion yuan to 2.36 trillion yuan during the same period, with a CAGR of 15.8% [4]. Strategic Initiatives - Meixin Health plans to deepen and expand collaborations with pharmaceutical and insurance companies, continue investing in its integrated payment platform, optimize healthcare payment and services through core infrastructure, and build a global healthcare network [5]. - The net proceeds from the IPO will be used to enhance services and solutions for pharmaceutical and insurance companies, accelerate the development of the integrated payment platform, strengthen infrastructure, and support strategic partnerships and acquisitions [6]. Market Context - The article notes a trend of insurance service companies going public, with several companies having listed since 2020, including Huize in the US and others in Hong Kong [6]. - As of this year, the number of insurance-related service companies that have gone public or are in the process of doing so has increased to seven, indicating a growing interest in the sector [6].

Core Viewpoint - The article discusses the increasing prevalence of "earn-out" agreements in China's venture capital landscape, highlighting the risks and consequences for entrepreneurs who fail to meet these targets, leading to significant financial burdens and potential bankruptcy [1][3][10]. Group 1: Current Market Trends - The case of Smartisan Technology's 15 million yuan loan dispute exemplifies the challenges faced by companies under earn-out agreements, with a ruling requiring repayment of principal plus interest at a rate of 6% [3]. - In 2023, several companies aiming for IPOs, such as Baishen Pharmaceutical and Youxun Medical, have triggered buyback clauses due to unmet targets, reflecting a broader trend in the market where 90% of private equity funds in China include such clauses [3][10]. - The contrast in earn-out agreement usage is stark, with China at 90% compared to only 2% in Silicon Valley, indicating a fundamental difference in venture capital ecosystems [3]. Group 2: Government and Institutional Responses - The Central Political Bureau of the Communist Party of China has introduced the concept of "patient capital," urging state-owned enterprises to lead by example in fostering a more sustainable investment environment [4][5]. - Various state-owned enterprises in cities like Shanghai and Beijing are taking steps to lower return requirements and extend fund durations, signaling a shift towards more supportive investment practices [5]. Group 3: Entrepreneurial Challenges - Entrepreneurs are increasingly finding themselves in precarious situations due to the pressure of earn-out agreements, with notable cases of founders facing severe consequences for failing to meet financial targets [6][10]. - The urgency to meet IPO deadlines is palpable, with approximately 130,000 investment projects and over 10,000 companies currently facing exit challenges [9]. - The article highlights the case of ADC, which achieved a remarkable IPO in Hong Kong but is burdened by significant losses and stringent earn-out conditions that could lead to high-interest buybacks if targets are not met [10]. Group 4: Market Dynamics and Future Outlook - The article notes a growing trend of companies turning to the Hong Kong stock market as a last resort for IPOs, with the market experiencing a resurgence in fundraising activities [10]. - The private equity secondary market is becoming increasingly active, with a notable rise in old stock transactions, indicating a shift in how liquidity crises are managed [12][14]. - The ongoing tension between short-term profit motives and long-term value creation is underscored, with the potential for a new path emerging through government-backed initiatives aimed at reducing the reliance on earn-out agreements [20].